Concord Biotech IPO: All You Need to Know
Concord Biotech Limited, an India-based R&D-driven biopharma company, has emerged as a global leader in the development and manufacturing of fermentation-based APIs (Active Pharmaceutical Ingredients). Established in 1984, the company has continuously expanded its presence worldwide and garnered a reputation for excellence in the field of immunosuppressants and oncology. This article dives into the history, objectives of the IPO, and key details surrounding the Concord Biotech Initial Public Offering (IPO) taking place from 4th to 8th Aug 2023. Concord Biotech: A Pioneering Journey
1. Early Beginnings:
Concord Biotech embarked on its journey in 1984 with a vision to make a difference in the biopharma industry. It started with a single product and gradually expanded its offerings, investing heavily in research and development. The company's relentless pursuit of excellence and dedication to innovation soon earned it recognition and accolades on both domestic and international platforms.
2. A Focus on R&D:
At the heart of Concord Biotech's success lies its unwavering focus on research and development. By harnessing the power of science and technology, the company has been able to develop cutting-edge products that address critical medical challenges. Their commitment to continuous improvement and innovation has allowed them to stay ahead of the curve in an ever-evolving industry.
3. Global Presence:
Concord Biotech has successfully established its presence in over 70 countries, catering to diverse markets including the USA, India, Europe, and Japan. This extensive global reach has not only bolstered the company's revenue but has also helped it gain invaluable insights into various healthcare systems and patient needs worldwide. Objectives of the IPO:
1. Listing Equity Shares
One of the primary objectives of the Concord Biotech IPO is to list its Equity Shares on the Stock Exchanges. By becoming a publicly listed company, Concord Biotech aims to enhance its visibility and reputation, attracting more investors and raising funds for future expansion and research initiatives.
2. Offer for Sale
Additionally, the IPO includes an Offer for Sale of up to 20,925,652 Equity Shares by the Selling Shareholder. This move allows early investors and stakeholders to monetize their investments and encourages broader participation in the company's growth story.
Concord Biotech IPO Details: For investors interested in participating in the growth story of SBFC Finance, the IPO details are as follows:
Dates: 4th to 8th Aug 2023
Price Band: 705 to 741
Lot Size: 20 shares
Issue Size: 1,551 Crores
Allotment Date: 11/12 Aug 2023
Listing Date: 18th Aug 2023
Retail Quota: 35%
GMP: +20% (Only for informing)
Like for Checking the IPO Allotment Status👇
Join our WhatsApp Group for Trading/Investment ideas & Market Updates👇
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on information published here. Any reader taking decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.